Uncategorized
Soleno sold at a discount to Neurocrine due to dwindling European prospects
Soleno sold at a discount to Neurocrine due to dwindling European prospects
The bleak European approval potential for Soleno Therapeutics’ genetic obesity drug essentially forced the US drugmaker to sell itself for less than it was once worth.
In a rare case, Soleno sold at a price … Read More